Merck & Co., Inc.
Close on Oct 30, 2026Market cap $368.89BP/E 119.6Yield 2.19%
Merck Zostavax (zoster vaccine live, legacy) by Year
Zostavax (zoster vaccine live, legacy) — Worldwide sales ($M) ($M)
Merck Zostavax (zoster vaccine live, legacy): $217M in FY2018, down 67.5% from a year earlier. No newer figure appears in the documents we track.
Where the FY2018 figure comes from
Source: Form 10-K (filed 2019-02-27) ↗
Reported in Form 10-Q / 10-K Segment & Product Sales Footnote & Form 8-K Table 3 / 3a / 3b.
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Zostavax (zoster vaccine live, legacy) — Worldwide sales ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2018 | Dec 31, 2018 | 217 | -67.5% | Form 10-K (filed 2019-02-27) ↗ |
| FY2017 | Dec 31, 2017 | 668 | -2.5% | Form 10-K (filed 2019-02-27) ↗ |
| FY2016 | Dec 31, 2016 | 685 | – | Form 10-K (filed 2019-02-27) ↗ |
Breakdown
What makes up zostavax (zoster vaccine live, legacy)
Cite this data
StockData. (2026). Merck Zostavax (zoster vaccine live, legacy) ($M), annual FY2016–FY2018 [Data set]. Compiled from Merck SEC filings and investor materials. https://stockdatahq.com/stocks/mrk/kpis/rev-zostavax
See every metric in the Merck KPI table. Data updated Oct 26, 2026.